Drug Trial Radar · NCT05952557
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
5,511
Actual
Start
Oct 5, 2023
Primary completion
Mar 4, 2030
Study completion May 6, 2037
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Austrian Breast & Colorectal Cancer Study Group
- First posted
- Jul 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Conditions
- Breast Cancer, Early Breast Cancer
Interventions
CamizestrantDrug
Camizestrant. Experimental. Administered orally
TamoxifenDrug
Tamoxifen. Comparator. Administered orally
AnastrozoleDrug
Anastrozole. Comparator. Administered orally
LetrozoleDrug
Letrozole. Comparator. Administered orally
ExemestaneDrug
Exemestane. Comparator. Administered orally
AbemaciclibDrug
Abemaciclib adjuvant treatment Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive breast cancer-free survival (IBCFS)Time frame: Up to 14 years
Locations
661 sites in 44 countries. Site status is shown where the registry gives one.
Research Site
Dothan, Alabama
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Fayetteville, Arkansas
Research Site
Duarte, California
Research Site
Fountain Valley, California
Research Site
Irvine, California
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Walnut Creek, California
Research Site
West Hollywood, California
Research Site
Aurora, Colorado
Research Site
Littleton, Colorado
Research Site
Littleton, Colorado
Research Site
New Haven, Connecticut
Research Site
Newark, Delaware
Research Site
Clearwater, Florida
Research Site
Fort Myers, Florida
Research Site
Gainesville, Florida
Research Site
Jacksonville, Florida
Research Site
Pembroke Pines, Florida
Research Site
Plantation, Florida
Research Site
Plantation, Florida
Research Site
St. Petersburg, Florida
Research Site
St. Petersburg, Florida
Research Site
Tallahassee, Florida
Research Site
West Palm Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Marietta, Georgia
Research Site
Thomasville, Georgia
Research Site
Chicago, Illinois
Research Site
Elmhurst, Illinois
Research Site
Naperville, Illinois
Research Site
Urbana, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Des Moines, Iowa
Research Site
Louisville, Kentucky
Research Site
New Orleans, Louisiana
Research Site
Scarborough, Maine
Research Site
Annapolis, Maryland
Showing 40 of 661 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.